EcoDrugPlus

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSCVAG00000004369
Gene Symbol: GABBR1
2 Cross references
163 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSCVAG00000006566
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSCVAG00000006407
Gene Symbol: LOC107083889
3 Cross references
193 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSCVAG00000018728
Gene Symbol: GLP2R
3 Cross references
204 Possible Orthologues:

Glucagon Receptor-Like

Ensembl ID : ENSCVAG00000001708
Gene Symbol: LOC107085001
2 Cross references
203 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSCVAG00000018781
Gene Symbol: LOC107101948
3 Cross references
207 Possible Orthologues:

Glucokinase

Ensembl ID : ENSCVAG00000019648
Gene Symbol: GCK
3 Cross references
216 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSCVAG00000022505
Gene Symbol: GBA1
3 Cross references
253 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSCVAG00000014977
Gene Symbol: GRIA1
3 Cross references
250 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSCVAG00000004499
Gene Symbol: GRIA2
4 Cross references
255 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSCVAG00000006640
Gene Symbol: GRIN1
3 Cross references
176 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSCVAG00000015111
Gene Symbol: GRIN2A
3 Cross references
223 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).